新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » EBioMedicine:鉴别出750多个生物标志物 助力癌症早期筛查

EBioMedicine:鉴别出750多个生物标志物 助力癌症早期筛查

来源:生物谷 2016-08-08 00:05

图片摘自:www.dailymail.co.uk

2016年8月3日 讯 /生物谷BIOON/ --近日,刊登在国际杂志EBioMedicine上的一项研究报告中,来自英国谢菲尔德大学的研究人员通过研究在血液中鉴别出了788个生物标志物(Biomarkers),这些生物标志物或可用于开发针对一般人群的早期癌症筛查测试技术。文章中,研究者表示,他们首次创建出了相关的癌症血液生物标志物的全面列表,这些生物标志物在过去5年里就已经开始被研究了。

研究人员表示,他们以过去5年里发表的1.9万篇研究论文开始他们的研究,这些研究论文都基于生物标志物对血液进行了相应的调查,而且系统性的评价方法(排除了少于50个病人的研究)将上述研究论文最后限定到4000个,这样一来研究者就可以对最终的生物标志物列表进行汇编了。

研究者Lesley Uttley说道,由于该领域有大量的出版物,而此前的一些综述文章也仅仅是去分析一种或一小类的生物标志物,而我们的数据挖掘方法将可以帮助我们对5年期间的相关研究进行分析,这就意味着我们将可以绘制出最大范围的血液生物标志物列表,而且这些生物标志物同早期癌症的诊断直接相关。

文章中,研究者调查了是否一种划算的筛查测试技术可以被用于一般人群来帮助鉴别早期的癌症患者;下一步他们将对生物标志物的详细信息进行分析,来检查这些生物标志物是否能够帮助进行准确的筛查检测,在早期阶段生物标志物将会根据癌症类型被分组,被验证的生物标志物也将用于临床研究中,同时研究者也将利用癌症患者的样本,并以健康个体为对照来检查其鉴别出癌症存在的有效性。

最终被证实可以成功用于筛查的生物标志物将会被考虑进入临床试验中,来观察是否这些筛查检测技术可以更好地在实际工作中使用。研究者认为,一旦验证过程和临床研究完成的话,我们将会得到一组包括50个生物标志物的系列,而且最终会进入到临床试验中去,为了完成这项验证过程,这项试验将需要6-8年时间来完成,但从理论上来讲,研究者将会在三年内对高风险的个体开展试验。

最后研究者表示,我们的愿望是新型的筛查技术可以在癌症早期阶段利用少量的生物标志物来对患者进行诊断,而并不需要鉴别出这些生物标志物和哪一类癌症相关,随后患者就会被进行多种特殊的检测,并且缩小对患者机体肿瘤类型的鉴别。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!点击 获取授权 。更多资讯请下载生物谷APP.

 

Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review

Lesley Uttley1, Becky L. Whiteman1, Helen Buckley Woods, Susan Harnan, Sian Taylor Philips, Ian A. Cree

 

Background The Early Cancer Detection Consortium is developing a blood-test to screen the general population for early identification of cancer, and has therefore conducted a systematic mapping review to identify blood-based biomarkers that could be used for early identification of cancer. Methods A mapping review with a systematic approach was performed to identify biomarkers and establish their state of development. Comprehensive searches of electronic databases Medline, Embase, CINAHL, the Cochrane library and Biosis were conducted in May 2014 to obtain relevant literature on blood-based biomarkers for cancer detection in humans. Screening of retrieved titles and abstracts was performed using an iterative sifting process known as “data mining”. All blood based biomarkers, their relevant properties and characteristics, and their corresponding references were entered into an inclusive database for further scrutiny by the Consortium, and subsequent selection of biomarkers for rapid review. This systematic review is registered with PROSPERO (no. CRD42014010827). Findings The searches retrieved 19,724 records after duplicate removal. The data mining approach retrieved 3990 records (i.e. 20% of the original 19,724), which were considered for inclusion. A list of 814 potential blood-based biomarkers was generated from included studies. Clinical experts scrutinised the list to identify miss-classified and duplicate markers, also volunteering the names of biomarkers that may have been missed: no new markers were identified as a result. This resulted in a final list of 788 biomarkers. Interpretation This study is the first to systematically and comprehensively map blood biomarkers for early detection of cancer. Use of this rapid systematic mapping approach found a broad range of relevant biomarkers allowing an evidence-based approach to identification of promising biomarkers for development of a blood-based cancer screening test in the general population.

相关会议推荐

2016生物标志物研讨会

会议时间:2016.09.09-2016.09.10     会议地点:上海

会议详情: http://www.bioon.com/z/2016biomarker/

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库